Clarke, J., Stinchcombe, T., Crawford, J., Mamdani, H., Gu, L., Ready, N., … Simon, G. (2022). 699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC). In Regular and Young Investigator Award Abstracts (pp. A730–A730). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2022-sitc2022.0699

Clarke, Jeffrey, Thomas Stinchcombe, Jeffrey Crawford, Hirva Mamdani, Lin Gu, Neal Ready, Andrew Nixon, et al. “699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC).” In Regular and Young Investigator Award Abstracts, A730–A730. BMJ Publishing Group Ltd, 2022. https://doi.org/10.1136/jitc-2022-sitc2022.0699.

Clarke J, Stinchcombe T, Crawford J, Mamdani H, Gu L, Ready N, et al. 699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC). In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022. p. A730–A730.

Clarke, Jeffrey, et al. “699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC).” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2022, pp. A730–A730. Crossref, doi:10.1136/jitc-2022-sitc2022.0699.

Clarke J, Stinchcombe T, Crawford J, Mamdani H, Gu L, Ready N, Nixon A, Baleviic S, Campa M, Gottlin L, Bushey R, Herndon J, Antonia S, Patz E, Simon G. 699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC). Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022. p. A730–A730.